TY - JOUR
T1 - Harnessing citizen science through mobile phone technology to screen for immunohistochemical biomarkers in bladder cancer
AU - Smittenaar, Peter
AU - Walker, Alexandra K.
AU - McGill, Shaun
AU - Kartsonaki, Christiana
AU - Robinson-Vyas, Rupesh J.
AU - McQuillan, Janette P.
AU - Christie, Sarah
AU - Harris, Leslie
AU - Lawson, Jonathan
AU - Henderson, Elizabeth
AU - Howat, Will
AU - Hanby, Andrew
AU - Thomas, Gareth J.
AU - Bhattarai, Selina
AU - Browning, Lisa
AU - Kiltie, Anne E.
N1 - Funding Information:
Funding: We acknowledge funding from Cancer Research UK, Cancer Research UK programme grant C5255/A15935 (AEK) and the research was supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC) (Molecular Diagnostics Theme/Multimodal Pathology Subtheme) (L.B.). A.W. was funded by an MRC studentship (MR/K501256/1).
Publisher Copyright:
© 2018 The Author(s).
PY - 2018/7/17
Y1 - 2018/7/17
N2 - Background: Immunohistochemistry (IHC) is often used in personalisation of cancer treatments. Analysis of large data sets to uncover predictive biomarkers by specialists can be enormously time-consuming. Here we investigated crowdsourcing as a means of reliably analysing immunostained cancer samples to discover biomarkers predictive of cancer survival. Methods: We crowdsourced the analysis of bladder cancer TMA core samples through the smartphone app 'Reverse the Odds'. Scores from members of the public were pooled and compared to a gold standard set scored by appropriate specialists. We also used crowdsourced scores to assess associations with disease-specific survival. Results: Data were collected over 721 days, with 4,744,339 classifications performed. The average time per classification was approximately 15 s, with approximately 20,000 h total non-gaming time contributed. The correlation between crowdsourced and expert H-scores (staining intensity × proportion) varied from 0.65 to 0.92 across the markers tested, with six of 10 correlation coefficients at least 0.80. At least two markers (MRE11 and CK20) were significantly associated with survival in patients with bladder cancer, and a further three markers showed results warranting expert follow-up. Conclusions: Crowdsourcing through a smartphone app has the potential to accurately screen IHC data and greatly increase the speed of biomarker discovery.
AB - Background: Immunohistochemistry (IHC) is often used in personalisation of cancer treatments. Analysis of large data sets to uncover predictive biomarkers by specialists can be enormously time-consuming. Here we investigated crowdsourcing as a means of reliably analysing immunostained cancer samples to discover biomarkers predictive of cancer survival. Methods: We crowdsourced the analysis of bladder cancer TMA core samples through the smartphone app 'Reverse the Odds'. Scores from members of the public were pooled and compared to a gold standard set scored by appropriate specialists. We also used crowdsourced scores to assess associations with disease-specific survival. Results: Data were collected over 721 days, with 4,744,339 classifications performed. The average time per classification was approximately 15 s, with approximately 20,000 h total non-gaming time contributed. The correlation between crowdsourced and expert H-scores (staining intensity × proportion) varied from 0.65 to 0.92 across the markers tested, with six of 10 correlation coefficients at least 0.80. At least two markers (MRE11 and CK20) were significantly associated with survival in patients with bladder cancer, and a further three markers showed results warranting expert follow-up. Conclusions: Crowdsourcing through a smartphone app has the potential to accurately screen IHC data and greatly increase the speed of biomarker discovery.
UR - http://www.scopus.com/inward/record.url?scp=85049622244&partnerID=8YFLogxK
U2 - 10.1038/s41416-018-0156-0
DO - 10.1038/s41416-018-0156-0
M3 - Article
C2 - 29991697
AN - SCOPUS:85049622244
VL - 119
SP - 220
EP - 229
JO - British Journal of Cancer
JF - British Journal of Cancer
SN - 0007-0920
IS - 2
ER -